As an oncology focused company, CIPREVO has identified and characterized its proprietary first-in-class drug-drug conjugates to treat patients with recurrent and/or metastatic solid tumors. The first drug-drug conjugate candidate of our pipeline is an antiproliferative agent which has demonstrated activity over a large spectrum of experimental cancer models. The candidate is currently evaluated in animal models.
CIPREVO based on this original approach has the ambition to build a robust portfolio of medicines to bring innovative solutions to patients with advanced cancers.